Next-gen intranasal Measles/Mumps-vectored vaccine platform for robust protection against SARS-CoV-2 and RSV
TS-075190 — PROBLEM
SARS-CoV-2, particularly the emerging Omicron variants, and respiratory syncytial virus (RSV) propose significant threat to global public health. Both SARS-CoV-2 and RSV are highly transmissible and significant risk of disease in infants and young children, older adults, and immunocompromis…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Hsu, Cheng Chih; Liang, Xueya
- Licensing Officer: Willson, Christopher
Intranasal bivalent vaccine platform for SARS-CoV-2 and RSV
TS-075189 — PROBLEM
SARS-CoV-2 and respiratory syncytial virus (RSV) drive significant global morbidity. New SARS-CoV-2 Omicron variants are causing frequent and often severe infections, while RSV remains a leading cause of severe respiratory disease in infants and young children, older adults, and immunocompr…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Liang, Xueya; Xu, Jiayu
- Licensing Officer: Willson, Christopher
Live attenuated measles virus vaccine strains for SARS-CoV-2 vaccine
TS-065451 — The Need
The need for effective vaccine development platforms has never been more pressing, especially in the face of evolving pathogens such as the measles virus. Current vaccine production methods often face challenges in achieving optimal expression levels and immunogenicity, hindering their eff…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Li, Anzhong; Liang, Xueya; Lu, Mijia; Niewiesk, Stefan
- Licensing Officer: Willson, Christopher
